12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tenofovir alafenamide fumarate: Phase II data

A double-blind, U.S. Phase II trial in 170 treatment-naïve patients with HIV-1 infection showed that once-daily TAF/elvitegravir/cobicistat/emtricitabine met the primary endpoint of non-inferiority to Gilead's Stribild elvitegravir/cobicistat/emtricitabine/tenofovir in the proportion of patients with HIV RNA levels <50 copies/mL at week 24 (87% vs. 90%). The TAF-based regimen also produced significantly smaller reductions from baseline to week 24 in BMD at the lumbar spine and hip vs. Stribild (p<0.005). Additionally, the TAF-based regimen led to small, significant improvements in serum creatinine and in calculated creatinine clearance vs. Stribild (p<0.02). No patients...

Read the full 439 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >